Literature DB >> 26397887

Treatment of giant cell arteritis.

Sumayya J Almarzouqi1, Michael L Morgan, Andrew G Lee.   

Abstract

PURPOSE OF REVIEW: Giant cell arteritis (GCA) remains a potentially blinding inflammatory vasculitis of the elderly. Because prolonged doses of corticosteroids remain the best established treatment, side-effects during treatment are common and potentially serious. This review addresses the challenges clinicians face in managing this disease. RECENT
FINDINGS: High-dose corticosteroids with slow tapering and close monitoring are the mainstay of treatment. Investigations into adjunctive treatment have yet to establish other agents as beneficial, but further research is ongoing with some promising results.
SUMMARY: GCA represents a challenging illness to clinicians because of its potential for causing blindness and the need for prolonged high doses of corticosteroids with their many complications.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26397887     DOI: 10.1097/ICU.0000000000000201

Source DB:  PubMed          Journal:  Curr Opin Ophthalmol        ISSN: 1040-8738            Impact factor:   3.761


  5 in total

Review 1.  The Treatment of Giant Cell Arteritis.

Authors:  Imran Jivraj; Madhura Tamhankar
Journal:  Curr Treat Options Neurol       Date:  2017-01       Impact factor: 3.598

2.  Corticosteroid Usage in Giant Cell Arteritis.

Authors:  Amritha Kanakamedala; Mariam Hussain; Ashwini Kini; Bayan Al Othman; Andrew G Lee
Journal:  Neuroophthalmology       Date:  2020-07-16

3.  Estimating the Cost of Illness of Giant Cell Arteritis in the United States.

Authors:  Joseph B Babigumira; Meng Li; Denise M Boudreau; Jennie H Best; Louis P Garrison
Journal:  Rheumatol Ther       Date:  2017-01-13

Review 4.  Giant cell arteritis: early diagnosis is key.

Authors:  Iyza F Baig; Alexis R Pascoe; Ashwini Kini; Andrew G Lee
Journal:  Eye Brain       Date:  2019-01-17

5.  Choroidal ischemia as one cardinal sign in giant cell arteritis.

Authors:  Antonio M B Casella; Ahmad M Mansour; Souza Ec; Rodrigo B do Prado; Rodrigo Meirelles; Keye Wong; Salma Yassine; Mário Luiz R Monteiro
Journal:  Int J Retina Vitreous       Date:  2022-09-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.